- Home
- AUTL vs PHAR Comparison
AUTL vs PHAR Comparison
Compare AUTL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- PHAR
- Stock Information
- Founded
- AUTL 2014
- PHAR 1988
- Country
- AUTL United Kingdom
- PHAR Netherlands
- Employees
- AUTL N/A
- PHAR N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- PHAR Health Care
- Exchange
- AUTL Nasdaq
- PHAR Nasdaq
- Market Cap
- AUTL 625.4M
- PHAR 951.7M
- IPO Year
- AUTL 2018
- PHAR N/A
- Fundamental
- Price
- AUTL $1.27
- PHAR $14.60
- Analyst Decision
- AUTL Strong Buy
- PHAR Strong Buy
- Analyst Count
- AUTL 5
- PHAR 3
- Target Price
- AUTL $9.12
- PHAR $30.00
- AVG Volume (30 Days)
- AUTL 4.4M
- PHAR 12.7K
- Earning Date
- AUTL 11-11-2025
- PHAR 10-23-2025
- Dividend Yield
- AUTL N/A
- PHAR N/A
- EPS Growth
- AUTL N/A
- PHAR N/A
- EPS
- AUTL N/A
- PHAR N/A
- Revenue
- AUTL $29,934,000.00
- PHAR $339,836,000.00
- Revenue This Year
- AUTL $641.63
- PHAR $16.63
- Revenue Next Year
- AUTL $109.21
- PHAR $6.77
- P/E Ratio
- AUTL N/A
- PHAR N/A
- Revenue Growth
- AUTL 185.17
- PHAR 22.44
- 52 Week Low
- AUTL $1.11
- PHAR $7.31
- 52 Week High
- AUTL $5.00
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- AUTL 24.20
- PHAR 56.71
- Support Level
- AUTL $1.30
- PHAR $13.63
- Resistance Level
- AUTL $1.46
- PHAR $15.27
- Average True Range (ATR)
- AUTL 0.09
- PHAR 0.96
- MACD
- AUTL 0.01
- PHAR -0.13
- Stochastic Oscillator
- AUTL 2.63
- PHAR 51.83
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.